SOCS1 gene transfer accelerates the transition to heart failure through the inhibition of the gp130/JAK/STAT pathway

Cardiovascular Research

Volumn 96, Issue 3, 2012, Pages 381-390

  Cittadini, Antonio ^a   Monti, Maria Gaia ^a   Iaccarino, Guido ^b,c   Castiello, Maria Carmina ^d   Baldi, Alfonso ^e   Bossone, Eduardo ^f   Longobardi, Salvatore ^g   Marra, Alberto Maria ^a   Petrillo, Valentina ^a   Saldamarco, Lavinia ^a   During, Matthew John ^h   Saccà, Luigi ^a   Condorelli, Gianluigi ⁱ  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

^d SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

^f IRCCS POLICLINICO SAN DONATO   (Italy)

^g Merck Serono Group   (Italy)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ Milan Unit   (Italy)

Author keywords

Cardiac hypertrophy; Gene therapy; Heart failure; SOCS

Indexed keywords

ANGIOPOIETIN 2; GLYCOPROTEIN GP 130; HEMAGGLUTININ; JANUS KINASE; PARVOVIRUS VECTOR; SUPPRESSOR OF CYTOKINE SIGNALING 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CLAMPING; APOPTOSIS; ARTICLE; CARDITIS; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME INHIBITION; GENE TRANSFER; HEART CONTRACTION; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HEART VENTRICLE SIZE; HISTOPATHOLOGY; MALE; MECHANICAL STRESS; MUSCLE STRETCHING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION; WALL STRESS;

ANGIOPOIETIN-2; ANIMALS; APOPTOSIS; CYTOKINE RECEPTOR GP130; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEART FAILURE; HEMODYNAMICS; HYPERTROPHY, LEFT VENTRICULAR; JANUS KINASE 1; MALE; MYOCARDIUM; PHOSPHORYLATION; RATS; RATS, WISTAR; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TIME FACTORS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR FUNCTION, LEFT;

EID: 84869448346     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs261     Document Type: Article

References (23)

1. Starr R, Wilson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ et al. A family of cytokine-inducible inhibitors of signaling. Nature 1997;387:917-921.
2. Nicola NA, Greenhalgh CJ. The suppressor of cytokine signaling (SOCS) proteins: important feedback inhibitors of cytokine action. Exp Hemat 2000;28:1105-1112.
3. Yasukawa H, Sasaki A, Yoshimura A. Negative regulation of cytokine signaling pathways. Annu Rev Immunol 2000;18:143-164. (Pubitemid 30365377)
4. Hilfiker-Kleiner D, Landmesser U, Drexler H. Molecular mechanism in heart failure. Focus on cardiac hypertrophy, inflammation, angiogenesis, and apoptosis. J Am Coll Cardiol 2006;48:A56-A66. (Pubitemid 44648642)
5. Hamanaka I, Saito Y, Yasukawa H, Kishimoto I, Kuwahara K, Miyamoto Y et al. Induction of JAB/SOCS-1/SSI-1 and CIS3/SOCS-3/SSI-3 is involved in gp130 resistance in cardiovascular system in rat treated with cardiotrophin-1 in vivo. Circ Res 2001;88:727-732. (Pubitemid 32378143)
6. Fisher P, Hilfiker-Kleiner D. Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects. Br J Pharmacol 2008;153:S414-S427. (Pubitemid 351341017)
7. Hanada T, Kobayashi T, Chinen T, Saeki K, Koga K, Minoda Y et al. IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J Exp Med 2006;203:1391-1397. (Pubitemid 43877600)
8. Davey GM, Heath WR, Starr R. SOCS1: a potent and multifaceted regulator of cyto-kines and cell-mediated inflammation. Tissue Antigens 2006;67:1-9. (Pubitemid 43381210)
9. Yakusawa H, Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 2003;4:551-556. (Pubitemid 36701338)
10. Hirota H, Chen J, Betz UA, Rajewsky K, Gu Y, Ross J et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during bio-mechanical stress. Cell 1999;97:189-198. (Pubitemid 29194270)
11. Hajjar RJ, Schmidt U, Matsui T, Guerrero JL, Lee KH, Gwathmey JK et al. Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci USA 1998;95:5251-5256. (Pubitemid 28208584)
12. Cittadini A, Monti MG, Iaccarino G, Di Rella F, Tsichlis PN, Di Gianni A et al. Adeno-viral gene transfer of Akt enhances myocardial contractility and intracellular calcium handling. Gene Ther 2006;13:8-19. (Pubitemid 41823847)
13. Cittadini A, Stromer H, Katz SE, Clark R, Moses AC, Morgan JP et al. Differential cardiac effects of GH and IGF-1 in the rat: a combined in vivo and in vitro evaluation. Circulation 1996;93:800-809. (Pubitemid 26052467)
14. Cittadini A, Isgaard J, Monti MG, Casaburi C, Di Gianni A, Serpico R et al. Growth hormone prolongs survival in experimental postinfarction heart failure. J Am Coll Cardiol 2003;41:2154-2163. (Pubitemid 36733540)
15. Cittadini A, Monti MG, Isgaard J, Casaburi C, Strömer H, Di Gianni A et al. Aldoster-one receptor blockade improves left ventricular remodelling and increases ventricular fibrillation threshold in experimental heart failure. Cardiovasc Res 2003;58:555-564. (Pubitemid 36694441)
16. Palmieri EA, Benincasa G, Di Rella F, Casaburi C, Monti MG, De Simone G et al. Differential expression of TNF-a, IL-6, and IGF-1 by graded mechanical stress in normal rat myocardium. Am J Physiol 2002;282:H926-H934. (Pubitemid 34654929)
17. Baldi A, Abbate A, Bussani R, Patti G, Melfi R, Angelini A et al. Apoptosis and postinfarction left ventricular remodeling. J Mol Cell Cardiol 2002;34:165-174. (Pubitemid 35222826)
18. Yasukawa H, Hoshijima M, Gu Y, Nakamura T, Pradervand S, Hanada T et al. Suppressor of cytokine signaling-3 is a biochemical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways. J Clin Invest 2001;108:1459-1467. (Pubitemid 33091983)
19. Tanimoto K, Saito Y, Hamanaka I, Kuwahara K, Harada M, Takahashi N et al. SOCS1/JAB likely mediates the protective effect of cardiotrophin-1 against lipopolysaccharide-induced left ventricular dysfunction in vivo. Circ J 2005;69:1412-1417. (Pubitemid 41560824)
20. Wang M, Markel T, Crisostomo P, Herring C, Meldrm KK, Lillemoe KD et al. Deficiency of TNFR1 protects myocardium through SOCS3 and IL-6 but not p38 MAPK or IL-1b. Am J Physiol 2007;292:H1694-H1699. (Pubitemid 46572390)
21. Sandek A, Wuest F, von Haehling S, Szabo T, Misgeld BJ, Doehner W et al. Upregula-tion of STAT-3, SOCS-1, pro-inflammatory and anti-inflammatory circulating mRNA gene expression in CHF patients with and without cachexia compared with healthy control subjects. (Abstract). Eur Heart J 2008;29:423.
22. Yasukawa H, Yajima T, Duplain H, Iwatate M, Kido M, Hoshijima M et al. The suppressor of cytokine signalling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury. J Clin Invest 2003;111:469-478. (Pubitemid 36228004)
23. Morisco M, Sadoshima J, Trimarco B, Arora R, Vatner DE, Vatner SF. Is treating cardiac hypertrophy salutary or detrimental: the two faces of Janus. Am J Physiol 2003;284:H1043-H1047. (Pubitemid 36348563)